BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the appointment of Matthew F. McManus as President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus brings over two decades of senior life sciences leadership experience and will succeed Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has a strong track record in the life sciences industry, having previously served as Executive Vice President and Chief Operating Officer for Azenta and as Senior Vice President and General Manager of Bio-Techne's Molecular Diagnostics Division. He also has a background in gene synthesis and cell & gene therapy markets. Kim Kelderman, Bio-Techne's Chief Operating Officer, expressed excitement for Dr. McManus' return and confidence in his ability to lead the Diagnostics and Genomics Segment through its next phase of growth.

MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.

Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular Diagnostics Division following its acquisition of Asuragen, where Dr. McManus served as President and CEO. Dr. McManus currently serves as the Chairman of the Board of Directors for ANSA, a company commercializing disruptive capabilities in gene synthesis and cell & gene therapy markets. Dr. McManus received his M.D. and Ph.D. from the University of Pennsylvania School of Medicine, his MBA from Boston College, and his B.A. in Economics from College of the Holy Cross.

"I am excited for Matt's return to Bio-Techne," said Kim Kelderman, Bio-Techne's Chief Operating Officer and in-coming Chief Executive Officer. "Matt's successful prior leadership of Bio-Techne's Molecular Diagnostics Division, combined with his breadth of life science experience and knowledge make him the perfect fit for this role. Matt is the ideal candidate to take the Diagnostics and Genomics Segment through its next phase of growth."

About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-appointment-of-matthew-f-mcmanus-as-president-diagnostics-and-genomics-segment-302026966.html

SOURCE Bio-Techne Corporation

FAQ

Who is the new President of Diagnostics and Genomics Segment at Bio-Techne Corporation?

Matthew F. McManus has been appointed as the new President of Diagnostics and Genomics Segment at Bio-Techne Corporation.

When will Matthew F. McManus assume his new role?

Matthew F. McManus will assume his new role as President, Diagnostics and Genomics Segment effective January 8, 2024.

What is the ticker symbol for Bio-Techne Corporation?

The ticker symbol for Bio-Techne Corporation is NASDAQ: TECH.

What is the background of Matthew F. McManus?

Matthew F. McManus has over two decades of experience as a senior life sciences leader and has served in various leadership roles in the industry.

What is the role of Kim Kelderman in Bio-Techne Corporation?

Kim Kelderman is currently the Chief Operating Officer of Bio-Techne Corporation and will become the Chief Executive Officer effective February 1, 2024.